Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 3.29% and Operating profit at 3.44% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 6.86%, it has a very attractive valuation with a 2.97 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,576 Million (Mid Cap)
43.00
NA
0.00%
-0.81
6.97%
1.49
Revenue and Profits:
Net Sales:
309 Million
(Quarterly Results - Mar 2026)
Net Profit:
40 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-42.13%
0%
-42.13%
6 Months
-52.11%
0%
-52.11%
1 Year
-46.32%
0%
-46.32%
2 Years
-43.15%
0%
-43.15%
3 Years
-77.49%
0%
-77.49%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
BMC Medical Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.29%
EBIT Growth (5y)
3.44%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.86
Sales to Capital Employed (avg)
0.32
Tax Ratio
9.84%
Dividend Payout Ratio
26.00%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
116.75%
ROE (avg)
9.36%
Valuation key factors
Factor
Value
P/E Ratio
43
Industry P/E
Price to Book Value
2.97
EV to EBIT
39.77
EV to EBITDA
35.19
EV to Capital Employed
12.66
EV to Sales
6.07
PEG Ratio
1.28
Dividend Yield
NA
ROCE (Latest)
31.83%
ROE (Latest)
6.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Bearish
Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
309.10
265.30
16.51%
Operating Profit (PBDIT) excl Other Income
50.90
66.00
-22.88%
Interest
0.20
1.70
-88.24%
Exceptional Items
-8.00
2.60
-407.69%
Consolidate Net Profit
39.90
72.90
-45.27%
Operating Profit Margin (Excl OI)
164.80%
222.50%
-5.77%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 16.51% vs 38.11% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -45.27% vs 44.07% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,148.70
836.50
37.32%
Operating Profit (PBDIT) excl Other Income
225.00
119.50
88.28%
Interest
5.50
3.30
66.67%
Exceptional Items
-8.60
7.50
-214.67%
Consolidate Net Profit
231.30
158.60
45.84%
Operating Profit Margin (Excl OI)
172.00%
110.70%
6.13%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 37.32% vs -25.14% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 45.84% vs -47.10% in Dec 2024
About BMC Medical Co. Ltd. 
BMC Medical Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






